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Transmission of hemorrhagic fever New World arenaviruses from
their rodent reservoirs to human populations poses substantial
public health and economic dangers. These zoonotic events are
enabled by the specific interaction between the New World
arenaviral attachment glycoprotein, GP1, and cell surface human
transferrin receptor (hTfR1). Here, we present the structural basis
for how a mouse-derived neutralizing antibody (nAb), OD01,
disrupts this interaction by targeting the receptor-binding surface
of the GP1 glycoprotein from Junín virus (JUNV), a hemorrhagic
fever arenavirus endemic in central Argentina. Comparison of our
structure with that of a previously reported nAb complex (JUNV
GP1–GD01) reveals largely overlapping epitopes but highly distinct
antibody-binding modes. Despite differences in GP1 recognition,
we find that both antibodies present a key tyrosine residue, albeit
on different chains, that inserts into a central pocket on JUNV
GP1 and effectively mimics the contacts made by the host TfR1.
These data provide a molecular-level description of how anti-
bodies derived from different germline origins arrive at equivalent
immunological solutions to virus neutralization.
arenavirus | glycoprotein | structure | antibody response |
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New World (NW) clade B arenaviruses (genus Mammar-enavirus) comprise a number of human pathogens, including
Junín virus (JUNV), Machupo virus (MACV), and Guanarito
virus (1, 2). These viruses are endemic to rodent populations in
rural areas of Argentina, Bolivia, and Venezuela, respectively,
and viral spillover into human populations can result in severe
hemorrhagic fever (HF) (3). Novel pathogenic NW arenaviruses
continue to be identified (4–6), underscoring a wide-scale need
for effective vaccines and therapeutics.
JUNV, the etiological agent of Argentine hemorrhagic fever
(AHF), constitutes one of the most dangerous NW arenaviruses,
putting an estimated 5 million people at risk (7, 8). JUNV in-
fection typically exhibits a rapid onset of disease (7–14 d) and
high mortality rates (15–30%) (7, 9, 10). There are no in-
ternationally approved drugs for preventing or treating NW
arenavirus HF. However, the successful development of a live,
attenuated JUNV vaccine, Candid#1, has proven that AHF can
be controlled (11). Similarly, virus-neutralizing immune plasma
from convalescent individuals has been successfully used for the
treatment of AHF (10, 12).
The JUNV envelope surface is decorated by trimeric multi-
functional glycoprotein complex (GPC) spikes. Each protomer in
the trimer consists of: a myristoylated (13) stable signal peptide,
an attachment subunit (GP1), and a transmembrane fusion
subunit (GP2) (14–19). Host-cell entry of JUNV and other clade
B arenaviruses is initiated by the interaction between the are-
naviral GP1 and the host transferrin receptor (TfR1) (20). The
GP1 subunit interacts with the apical domain of TfR1, distal
from natural transferrin and hereditary hemochromatosis pro-
tein recognition sites (21, 22). A primary determinant of zoonotic
spread of clade B arenaviruses is the ability of the GP1 to rec-
ognize the human TfR1 ortholog (20, 23).
The JUNV GPC spike comprises the primary target for neu-
tralizing immune responses (24) and three GPC-specific mouse-
derived nAbs—GD01, OD01, and GB03—have shown promise
in animal models of infection (25), raising hopes for the devel-
opment of mAb-based therapeutics. The structural basis for virus
neutralization by one such mAb, GD01, has been elucidated,
revealing an epitope on the GP1 glycoprotein that overlaps with
the hTfR1 binding site (26). Here, we sought to determine the
molecular basis for JUNV neutralization by the similarly derived
mAb OD01. Our X-ray crystallographic investigation reveals that
although OD01 bears highly contrasting paratopes and exhibits a
smaller binding surface on JUNV GP1 than GD01, both antibodies
effectively mimic the contacts made by the host TfR1 during viral
attachment. This analysis demonstrates that antibodies derived
from different germlines can achieve this highly effective immu-
nological solution.
Results
Structure Determination of JUNV GP1–OD01 Fab Complex. The
mouse-derived neutralizing antibody, OD01 (clone OD01-AA09),
has been shown to target the glycoprotein spike of JUNV (24). To
refine the specificity of the nAb OD01, we performed an
ELISA using our recombinantly derived JUNV GP1 (residues
D87–V231) as an antigen (Fig. 1A). Although nAb OD01 bound
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to JUNV GP1 at concentrations as low as 0.01 μg·mL−1, no
cross-reactivity was observed with MACV GP1 or the lym-
phocytic choriomeningitis virus (LCMV) GP1-negative control. To
facilitate structure determination, recombinant JUNV GP1 (Fig.
1B) was deglycosylated with endoglycosidase F1 (endoF1) (SI
Appendix, Fig. S1A) and crystallized in complex with the antigen-
binding fragment (Fab) of OD01. The structure of the complex
was solved to 1.95-Å resolution (SI Appendix, Table S1). The
amino acid sequence of OD01 was predicted crystallographically
and used to create an engineered Fab fragment (herein referred
to as eOD01) capable of stably and specifically binding JUNV
GP1 (SI Appendix, Figs. S1 B and C and S2). Recombinant ex-
pression, crystallization, and structural determination of eOD01
with JUNV GP1 to 1.85-Å resolution (Fig. 1C and SI Appendix,
Table S1) revealed identical binding modes for the JUNV GP1–
OD01 and JUNV GP1–eOD01 complexes (0.2 Å rmsd over
569 Cα residues) (SI Appendix, Fig. S3). We note that it is pos-
sible for subtle amino acid sequence differences that could not
be distinguished by crystallographic analysis at this resolution
(e.g., Asn vs. Asp) to exist between OD01 and our engineered
version. However, the near identical mode of JUNV GP1 rec-
ognition provides a realistic model for JUNV neutralization by
the native antibody.
Structural Characterization of JUNV GP1–eOD01. Two JUNV GP1–
eOD01 Fab complexes were present in the asymmetric unit, with
minimal structural differences observed between crystallo-
graphically related JUNV GP1 and eOD01 Fab pairs (SI Ap-
pendix, Fig. S4 A and B). As previously observed (26), JUNV
GP1 forms a compact α/β-fold (Fig. 1B). The two eOD01 Fabs in
the asymmetric unit recognize JUNV GP1 nearly identically,
with both binding to the convex face of their cognate GP1
molecules at a site overlapping that used for TfR1 attachment
(Fig. 1 C and D) (0.6 Å rmsd over 575 equivalent JUNV GP1–
eOD01 complex Cα atoms) (SI Appendix, Fig. S4C). The JUNV
GP1–eOD01 interaction interface occludes ∼1,200 Å2 of solvent-
accessible surface area. Complementarity-determining regions
(CDRs) from both the heavy and light chains of eOD01 form
contacts with JUNV GP1, indicating that the chains are likely to
be mutually required for antigen recognition (Figs. 1C and 2A
and Table 1).
Although the heavy-chain CDR loops H2 and, especially,
H3 make a sizeable contribution to the eOD01–GP1 interface,
the interaction is dominated by the CDR1 from the light chain
(CDR L1), which extends a 15-amino acid loop deep into a
central pocket on the β-sheet of JUNV GP1 (Figs. 1C and 2A).
Tyr30B from eOD01 CDR L1 [Chothia numbering scheme (27)]
appears to be of chief importance to this interface, where the
side-chain hydroxyl group hydrogen bonds with JUNV GP1 side-
chains Ser111 and Asp113 at the tip of the third strand of JUNV
GP1 (Fig. 2A). From the opposite side of the central pocket,
the Tyr30BeOD01 main chain is stabilized by an additional
hydrogen-bonding interaction with the guanidinium group of
Arg165JUNV GP1 (Fig. 2A). Additionally, the aromatic ring of
Tyr30BeOD01 is surrounded by the side chains of Ile115JUNV GP1,
Val117JUNV GP1, Ile174JUNV GP1, and Lys216JUNV GP1, which con-
tribute to the hydrophobicity of the pocket (SI Appendix, Fig. S5).
Although N-linked glycans decorate the periphery of the
JUNV GP1 β-sheet (Fig. 1B), the crystallographically observed
antibody–antigen interaction is predominantly carbohydrate
Fig. 1. Reactivity and binding mode of the JUNV-specific neutralizing antibody, OD01. (A) ELISA analysis of nAb OD01 titrated against immobilized are-
navirus GP1 glycoproteins. Wells were coated with JUNV GP1, MACV GP1, or LCMV GP1 (negative control). Error bars, SD (n = 3), not shown when smaller than
symbol size. (B, Upper) Domain organization of the JUNV glycoprotein precursor [produced using the DOG software (53)]. The JUNV GP1 construct used for
crystallization is highlighted as a rainbow. Diamond-shaped symbols designate N-linked glycosylation sequons (NXT/S, where X ≠ P) with sites observed to be
occupied in the crystal structure colored yellow. GP1, attachment glycoprotein; GP2, fusion glycoprotein; IV, intravirion domain; SKI-1/S1P, subtilisin-like kexin
protease-1/site-1-protease; SSP, stable signal peptide; TM, transmembrane domain. (Lower) JUNV GP1 from the JUNV GP1–Fab eOD01 cocrystal structure.
JUNV GP1 is shown as a cartoon and colored as a rainbow ramped from blue (N terminus) to red (C terminus). Primary interaction loops involved in
eOD01 binding are labeled and N-linked glycans are shown as sticks. Glycosylation was not detected at Asn95, which is indicated as a white sphere.
(C) Structure of JUNV GP1 in complex with eOD01. CDRs contributing to JUNV recognition are colored pink (heavy chain) and green (light chain). The side
chain from residue Tyr30B of the eOD01 light chain is shown in stick representation. VH, VL, CH1, and CL denote the antibody variable heavy, variable light,
constant heavy 1, and constant light-chain domains, respectively. The positions of crystallographically observed N-linked glycosylation on JUNV GP1 are
indicated as yellow spheres. (D) Structure of MACV GP1 in complex with hTfR1 (22). Only the apical domain of hTfR1 (blue) is shown for clarity. Regions of
hTfR1 that interact with MACV are marked as thick tubes and the side chain from the conserved tyrosine residue, Tyr211, is shown in stick representation.
2 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1702127114 Zeltina et al.
independent (SI Appendix, Fig. S4C). Electron density corre-
sponding to at least one GlcNAc moiety was observed at three
of the four N-linked glycosylation sequons: Asn105, Asn166,
Asn178, but not Asn95. A chain of at least six N-linked glycan
moieties (Man4GlcNAc2) was ordered at Asn178 in both mole-
cules of the asymmetric unit, suggestive that the di-N-ace-
tylchitobiose core of this glycan is protected by the surrounding
proteinous environment from endoF1 digestion (Fig. 1B and
SI Appendix, Fig. S6A). Upon overlay, we note that the exten-
sions of the Asn178 glycans form subtly different conformations
in the two molecules of the asymmetric unit (SI Appendix,
Fig. S6B), indicating that differential packing environments
may play a role in stabilizing the termini of these otherwise
flexible glycans.
Fig. 2. Comparison of the JUNV GP1–eOD01, JUNV GP1–GD01, and MACV GP1–hTfR1 complex interfaces. (A, Left) Interaction between JUNV GP1 and
eOD01. JUNV GP1 is shown as a gray cartoon, CDR loops of eOD01 are colored as indicated [Chothia numbering scheme (27)]. VH, VL, CH1, and CL denote the
antibody variable heavy, variable light, constant heavy 1, and constant light-chain domains, respectively. (Upper Right) CDR loop use by eOD01 in the JUNV
GP1 complex with the CDR loop carrying Y30B denoted with an asterisk; calculated using the PDBePISA server (54) and measured in buried surface area (Å2).
(Lower Right) Close-up view of the JUNV GP1–eOD01 interface with intermolecular hydrogen bonds (distance ≤ 3.5 Å) highlighted with dashes and the
participating residues shown as sticks. (B, Left) Structure of JUNV GP1 in complex with GD01 (26), as presented in A. (Upper Right) CDR loop use by GD01 in the
JUNV GP1 complex with the CDR loop carrying Y98 denoted with an asterisk, calculated as inA (54). (Lower Right) Close-up view of the JUNV GP1–GD01 interface.
Hydrogen bonds formed by the same JUNV GP1 residues as in A are shown, as well as bonds involving the JUNV GP1 loop 7. (C) Interaction between the apical
domain of hTfR1 (blue) in complex with MACV GP1 (22) (pale green), with zoom-in panel as presented in B. (D) Relative orientation of the Y211hTfR1 (blue),
Y98GD01 CDRH3 (pink), and Y30BeOD01 CDRL1 (dark green) residues with respect to JUNV GP1 (white cartoon) and MACV GP1 (pale green cartoon).
Table 1. Comparison of JUNV GP1–eOD01 and JUNV GP1–GD01 interfaces
Antibody properties eOD01 heavy chain eOD01 light chain GD01 heavy chain GD01 light chain
Amino acid length of CDR loops H1: 7 (94%)* L1: 15 (9%)*,† H1: 7 (94%)* L1: 11 (31%)*
H2: 6 (81%)* L2: 7 (99%)* H2: 6 (81%)* L2: 7 (99%)*
H3: 11 (13%)* L3: 9 (77%)* H3: 15 (1%)*,† L3: 9 (77%)*
Footprint on JUNV GP1, Å2‡ ∼400 ∼200 ∼600 ∼300
JUNV GP1 residues contacted‡,§ 11 10 21 11
Hydrogen bonds‡,§ 7 4 13 7
*Values in parenthesis indicate the frequency of the particular CDR loop length in Mus musculus, calculated using the abYsis
system (29).
†Dominant paratopes in each respective Fab.
‡Calculated using the PDBePISA server (54).
§Calculations done for the JUNV GP1-eOD01 complex 1, as defined in the legend to SI Appendix, Fig. S4.








Although glycans do not appear to play a role in eOD01–
JUNV GP1 complex formation, the presence of glycosylation on
the GP1 does affect the potency of antibody-mediated neutrali-
zation. For example, OD01 and GD01 neutralize rLCMV dis-
playing an XJ Clone 3 JUNV vaccine strain glycoprotein, which
lacks the Asn166 glycosylation motif, more potently than the
autologous virus, in which this glycosylation motif has been re-
stored (28). Considering the proximity of Asn166 to the JUNV
GP1–antibody interface (Fig. 1C), it seems possible that the
presence of native N-linked glycosylation at this site may in-
terfere with the antibody–glycoprotein interaction.
eOD01 and GD01 Are Distinct yet Target Overlapping Epitopes. The
structure of GD01 in complex with JUNV GP1 has been pre-
viously reported (26) and provides an opportunity to compare
how JUNV is neutralized by two unique mouse-derived anti-
JUNV nAbs (Figs. 2 A and B and 3 and Table 1). Structural
comparison of these two complexes reveals that the antibodies
exhibit differing footprint sizes on the GP1 surface (∼600 and
∼900 Å2 for eOD01 and GD01, respectively), with both epitopes
overlapping the predicted receptor binding site (RBS). Despite
contacting the same region of the JUNV GP1 surface, the two
nAbs exhibit highly contrasting modes of antigen recognition,
where the light- and heavy-chain epitopes on JUNV GP1 are
largely swapped (Figs. 2 A and B and 3). For example, GP1 loop
3 residues Asp114 and Ala116 are stabilized by intermolecular
hydrogen bonds in both GP1–nAb complexes. However, al-
though these interactions are mediated by nAb heavy-chain
residues Arg95, Thr97, and Thr99 in the GP1–eOD01 com-
plex, light-chain residues Ser31, Ala32, and Ser92 provide these
contacts in the GP1–GD01 interface (Fig. 2 A and B).
These contrasting modes of antigen recognition are reflected in
the amino acid length and sequence of the dominant CDR regions
(Table 1 and SI Appendix, Figs. S7 and S8). For example, whereas
the CDR L1 loop of eOD01 is 15 amino acids in length, charac-
teristic of the mouse IGKV3 germline family, the corresponding
CDR L1 region of GD01 is derived from a different mouse
germline group IGKV6 and is 11 amino acids (SI Appendix,
Fig. S7), a length more commonly observed both in mouse and
human antibodies (29) (Table 1). Interestingly, the eOD01
light-chain protein sequence shows little deviation from the
germline IGKV3-2*01 V-gene (SI Appendix, Fig. S7), with only
one mutation in the CDR L1 region. Instead of CDR L1, the
GD01–GP1 interaction is dominated by the 15-amino acid
CDR H3, which is uncommonly long for the species, with only
∼3% of the sequenced mouse CDR H3s displaying a length equal
to or greater than 15 amino acids (29) (Table 1).
A Shared Feature of Receptor Mimicry. We note a striking com-
monality between eOD01 and GD01: Tyr30B from the L1 loop
of eOD01 occupies a position in the central pocket of JUNV
GP1 that largely overlaps with that of Tyr98 from the CDR
H3 loop of GD01 (Fig. 2 A and B). This position is also highly
similar to the location of Tyr211hTfR1 in the MACV GP1–hTfR1
complex (22) (Fig. 2 C and D), the only clade B arenavirus gly-
coprotein–receptor structure reported to date. Tyr211 is a key
residue in the GP1–hTfR1 interface (22) and conserved across
all TfR1 orthologs that support NW arenavirus entry (23, 30, 31).
Although we note that sequence and structural variation between
the MACV GP1 and JUNV GP1 RBS exist, the colocalization
of Tyr30BeOD01 and Tyr98GD01 at the Tyr211hTfR1 recognition
site indicates that both nAbs effectively mimic TfR1-mediated
arenaviral attachment.
Discussion
NW hemorrhagic fever arenaviruses pose a significant threat to
human health, underscoring the need for effective vaccines and
antiviral therapies. Although practical limitations of convales-
cent serum therapy exist, passive transfer of immunoglobulins
remains an effective AHF treatment in a postexposure context
(10, 12), confirming that the neutralizing antibody response is
crucial for controlling JUNV infection.
Fig. 3. Footprints of hTfR1, eOD01, and GD01 plotted onto MACV and JUNV GP1. (A) Surface representations of MACV GP1 (Left) and JUNV GP1 (Center and
Right). The footprint of hTfR1 on MACV GP1 is shown in blue. Dark blue represents amino acid residues conserved between MACV GP1 and JUNV GP1 (both
identical and similar residues); not conserved residues are in light blue (including deletions and insertions). The antibody heavy (VH) and light (VL) chain
footprints on JUNV GP1 are colored pink and green, respectively. Residues contacted by both chains are shown in gray. (B) Sequence alignment of JUNV
GP1 residues 87–231 with the corresponding residues of the MACV GP1 [determined by Clustal Omega (55), plotted by ESPript (56), and adjusted by hand].
Secondary structure elements are shown with arrows representing β-strands (β1–β7) and spirals representing α (α1–2) and 310-helices (η1–5). Colored squares
under the sequence alignment mark GP1 residues contacted by hTfR1, eOD01, and GD01; colored as in A. Black-bordered squares indicate residues not
conserved between the JUNV GP1 sequences used for cocrystallization with OD01 (shown) and GD01 (i.e., Q109K and Q121E). Black dots denote JUNV
GP1 residues forming minor contacts with eOD01, which were only observed in one of the two complexes in the asymmetric unit.
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Our structural analysis reveals that antibodies derived from
different germlines can be directed to mimic host–receptor in-
teractions on JUNV GP1. Similarly, neutralizing RBS-targeting
antibodies of differing germline origins have been observed in
other viruses, including influenza virus, HIV, and poliovirus (32–
34). In the case of influenza virus, it has been possible to rec-
ognize a signature binding motif on the CDR H3 loop (33).
Here, we demonstrate that a key immunoglobulin tyrosine resi-
due, which mimics the critical Tyr211hTfR1, can be located on the
CDR loops of either heavy or light chains of anti-JUNV nAbs.
Although our structural analysis suggests that nAbs use the
functionally conserved TfR1 binding site on the NW arenaviral
GP1 as a major target, we note that OD01, GD01, and other
monoclonal antibodies reported by Sanchez et al. (24) do not
cross-react with MACV GP1 or other clade B arenaviruses (22,
24, 35) (Fig. 1A and SI Appendix, Fig. S9). We suggest that the
inability of these antibodies to cross-react with MACV GP1, the
most closely related pathogenic NW arenavirus species, may be
because of the specific sequence differences and structural var-
iations among the GP1 glycoproteins (Fig. 3). Indeed, this hy-
pothesis is supported by overlay analysis of our eOD01–JUNV
GP1 complex with MACV GP1, which indicates major clashes
with the elongated helical C-terminal region of the MACV
GP1 that would interfere with OD01 recognition (Fig. 2D and SI
Appendix, Fig. S10). Cross-neutralizing antibodies capable of
targeting both JUNV and MACV GP1 would likely need to
accommodate for the differential presence of these helices, as
well as for the sequence variation at the RBS.
Although few JUNV-specific nAbs have been reported to
date, Mahmutovic et al. (26) have demonstrated that the hTfR1
binding site on the GP1 glycoprotein is a major target for anti-
bodies generated during natural human infection. Indeed, the
overlap of OD01 and GDO01 footprints (Fig. 3) is consistent
with the existence of an immunodominant epitope at the RBS
of JUNV GP1 (26, 35). As a result, the identification of nAbs
targeting other neutralizing epitopes is an important consid-
eration for developing synergetic, noncompeting combinations
of therapeutic anti-JUNV mAbs. Indeed, Robinson et al. (36)
reported a range of neutralizing epitopes among human mAbs
raised upon infection by Lassa virus (LASV), a more distantly
related Old World arenavirus. Of the 16 identified anti-LASV
nAbs, 13 require the assembled GPC for binding, whereas 3 re-
quire only the GP1 (36). Thus, emerging techniques in mAb
generation, such as the isolation of antigen-specific B cells (37)
against an intact prefusion GPC spike antigen, may reveal anti-
bodies capable of targeting alternative non-RBS epitopes on the
JUNV glycoprotein surface.
Materials and Methods
Protein Expression and Purification. The cDNA of JUNV (GenBank accession no.
ACO52428), MACV (AAS77647), and LCMV (CAC01231) glycoproteins was
synthetized by GeneArt (Life Technologies). For crystallization, a construct of
JUNV GP1 (D87−N232) was derived by high-throughput cloning into the
pOPINTTGneo mammalian expression vector (38). Constructs of MACV GP1
(E87–F257), LCMV GP1 (M81–K256), and an additional construct of JUNV
GP1 with an amino acid C-terminal truncation (D87–V231; to facilitate
cloning) were cloned into the pHLsec vector (39) for ELISA experiments.
Proteins were expressed in transiently transfected HEK 293T cells (ATCC CRL-
1573) in the presence of the α-mannosidase inhibitor, kifunensine, as pre-
viously described (39). Cell supernatants were harvested 4 d after trans-
fection, clarified, and diafiltrated against a buffer containing 10 mM Tris
(pH 8.0) and 150 mM NaCl (ÄKTA Flux diafiltration system; GE Healthcare).
Glycoproteins were purified by immobilized nickel-affinity chromatography
(5-mL HisTrap FF crude column and ÄKTA FPLC system; GE Healthcare) fol-
lowed by size-exclusion chromatography (SEC) using a Superdex 200 10/300
Increase column (GE Healthcare), equilibrated in 10 mM Tris pH 8.0, 150 mM
NaCl buffer. To enable crystallogenesis, JUNV GP1 was partially deglycosy-
lated by endoF1 treatment (40). Following deglycosylation, JUNV GP1 was
repurified by SEC, as described above.
The mAb, OD01 (clone OD01-AA09), was obtained through BEI Resources
(Biodefense and Emerging Infections Research Resources Repository). The Fab
fragment of OD01was produced using the PierceMouse IgG1 Fab and F(ab′)2
Preparation Kit (Thermo Fischer Scientific) following the manufacturer’s
protocol. The eOD01 Fab fragment heavy- and light-chain genes were syn-
thetized by GeneArt (Life Technologies), and the codon optimized cDNAs
were cloned into the pHLsec vector (39). A C-terminal His6-tag was included
in the heavy chain construct and both chains were coexpressed [1:1 (wt/wt)
ratio of Fab heavy to light chain expressing plasmids] in HEK293T cells and
purified, as described above.
For ELISA experiments, the eOD01 Fab fragment variable domains were
cloned into human IgG heavy and κ light-chain full-length constant region
expression vectors (41). The recombinant antibody was expressed in HEK293
Freestyle cells cotransfected with heavy- and light-chain antibody expressing
plasmids at a 1:1 (wt/wt) ratio with PEImax [1:3 (wt/wt) PEI:total DNA;
Polysciences]. Transfections were performed according to the manufacturer’s
protocol, antibody supernatant was harvested 4 d following transfection,
and clarified. Chimeric eOD01 antibody was purified over a protein A col-
umn, eluted with 0.1 M glycine (pH 3.5), concentrated, and buffer ex-
changed into PBS.
Crystallization and Structure Determination. Before crystallization, Fab
OD01 and JUNV GP1weremixed in a 1:1.1 molar ratio. Initial OD01 Fab–JUNV
GP1 complex crystals were obtained at room temperature using the sitting-
drop vapor-diffusion method (42) by mixing 100 nL of protein (at a con-
centration of 6.0 mg·mL−1) in 10 mM Tris pH 8.0, 150 mM NaCl buffer with
100 nL of precipitant containing 20% (vol/vol) 2-propanol, 20% (wt/vol) PEG
4000, and 0.1 M trisodium citrate (pH 5.6). Crystallization drops were
equilibrated against 95 μL of a precipitant-containing reservoir. X-ray dif-
fraction data were collected from several optimized crystals grown sepa-
rately in the presence of the precipitant plus one of the following additives:
100 nL 6% (wt/vol) D-trehalose dihydrate (added to the crystallization drop),
100 nL 6% (wt/vol) D-galactose (added to the crystallization drop), or 20 μL
40% (vol/vol) 1-propanol (added to the reservoir).
For crystallization, recombinantly produced Fab eOD01 and JUNV GP1,
were mixed at a 1:1.2 molar ratio. After complex formation, excess JUNV
GP1 was removed by SEC and the complex was crystallized, as described
above. X-ray diffraction data were collected from several optimized crystals
grown separately in the presence of the original precipitant plus one of the
following additives: 20 μL of 40% (vol/vol) 1-propanol (added to the reser-
voir) or 40% (vol/vol) acetone (added to the reservoir). Crystals were cry-
oprotected with 25% (vol/vol) glycerol and flash-frozen in liquid nitrogen.
X-ray data were recorded at Beamline I02 at the Diamond Light Source
(Didcot, UK) on a Pilatus 6MF detector (Dectris). X-ray data were indexed,
integrated, and scaled with XIA2 (43). The high-resolution cut-off for the
data was determined by analysis of CC1/2, as defined by Karplus and Die-
derichs (44). The structure of the OD01–JUNV GP1 complex was phased by
molecular replacement with PHASER (45) using the crystal structures of a
mouse Fab fragment [PDB ID code 3WII (46)] and MACV GP1 [PDB ID code
2WFO (19)] as search models. Iterative model building was performed with
COOT (47) to obtain a model of OD01 Fab with an amino acid sequence that
was found to provide the best fit to the experimental electron density
(eOD01 sequence). Structure refinement was performed with Refmac5 (48)
in the CCP4 suite including translation–libration–screw–rotation restraints
(49, 50) and locally defined noncrystallographic symmetry. The eOD01–JUNV
GP1 complex structure was determined as described above, except the
OD01–JUNV GP1 structure was used for phasing by molecular replacement.
The final refined structure was validated with MolProbity (51). Conforma-
tional validation of carbohydrate structures was performed using the Pri-
vateer software (52).
ELISA Experiments. ELISA plates (High Bind Microplate; Corning) were coated
with viral glycoproteins in PBS (3 μg·mL−1) overnight at 4 °C. Plates were
washed four times with PBS-T (PBS with 0.05% Tween-20) and blocked for
1 h with 5% nonfat milk in PBS-T. The mouse-derived antibodies [OD01
(clone OD01-AA09), GD01 (clone GD01-AG02), QC03 (clone QC03-BF11),
GB03 (clone GB03-BE08), and LD05 (clone LD05-BF09) (24), obtained through
BEI Resources] and the purified eOD01 chimeric antibody were serially di-
luted in 5% nonfat milk/PBS-T and incubated with the viral glycoproteins for
2 h, then plates were washed as above. Mouse-derived antibodies were
detected using alkaline phosphatase-conjugated goat anti-mouse IgG (Fab
specific) antibody (Sigma), and the chimeric eOD01 antibody was detected
using alkaline phosphatase conjugated goat anti-human F(ab′)2 antibody
(Thermo Fisher Scientific). Reactions were incubated with the secondary
antibody for 1 h and the plates were washed as above. Binding was detected








with the p-nitrophenyl phosphate substrate (Sigma) and the plates were
read at 405 nm.
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